ABSTRACT ATP-stimulated prostacyclin release from veins was investigated using epigastric veins isolated from hamsters. Veins were perfused with MOPS-buffered PSS. ATP was administered into the perfusate and the bath solution (MOPS-PSS) was collected and assayed for the presence of the stable prostacyclin metabolite, 6-keto-PGF 1 . ATP (100 µM) resulted in reproducible increases in bath concentration from 73 22 to 279 50 pg/ml (P<0.05, n=5). This response was abolished by indomethacin (10 µM, P<0.05).
INTRODUCTION
Previous studies from our laboratory have demonstrated an obligatory role for the venular endothelium during the onset of exercise-induced arteriolar dilation, or functional hyperemia, in hamster cremaster muscle (23) . In addition, the cyclooxygenase inhibitor, indomethacin, inhibited this microcirculatory response to skeletal muscle stimulation (17) . Ellsworth et al (9) showed that red blood cells could release ATP in response to hypoxia and decreased pH, conditions which prevail in the venous microcirculation during exercise. A recent study has reported a correlation between venous plasma ATP concentration and the oxygenation state of hemoglobin in humans (12) . We have further demonstrated that ATP infused into venules paired with arterioles results in dilation of the adjacent arteriole in hamster cremaster muscle, an effect which was blocked by disruption of the venular endothelium or by global administration of indomethacin (15) .
The results of these studies suggest that during periods of increased skeletal muscle metabolism, such as during exercise, red blood cells release ATP in the venular blood in response to stimuli such as hypoxia, hypercapnia or decreased pH. ATP then stimulates the venular endothelium to produce prostacyclin, which diffuses to and dilates the adjacent arteriole. We recently demonstrated that increases in intraluminal concentration of ATP stimulated the release of prostacyclin from hamster epigastric veins via an increase in intracellular calcium concentration (5) . The first aim of the present study was to determine whether the endothelium is the source of the prostacyclin released in response to ATP in these veins.
Once released from cells, extracellular ATP is rapidly hydrolyzed to ADP, AMP and adenosine via extracellular ecto-nucleotidases. The fate of extracellular ATP has 1 R- 00468-2002.R1 been reviewed elsewhere (3, 13, 28) . ATP and ADP mediate their vasodilatory effects via P2Y receptors while adenosine and AMP mediate their vasodilatory effects via adenosine (P1) receptors. Subtypes of both receptors have been identified on vascular endothelial cells (22) . The relative contribution of P2Y and P1 receptors to ATP-mediated vasodilation remains controversial and thus, a second aim of the present study was to determine whether ATP-stimulated prostacyclin release was mediated via activation of P2Y or P1 receptors. R-00468-2002 .R1
MATERIALS AND METHODS
The experimental protocols for this study were approved by the Institutional Animal Care and Use Committee of the University of Mississippi Medical Center and were carried out according to both the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health and the guidelines of the Animal Welfare Act.
General procedures: Male golden hamsters (140-200g) were anesthetized with pentobarbital sodium (60 mg/kg, intraperitoneal). The hindlimb vasculature was exposed by an incision of the skin and the tissues were kept moist by superfusing them with warm physiological salt solution (PSS) of the following composition (in mM): 131.9 NaCl, 4.7 KCl, 2.0 CaCl 2 , 1.2 MgSO 4 and 20 NaHCO 3, equilibrated with 95% N 2 , 5% CO 2 . With the use of an operating microscope, the superficial epigastric vein was separated from the adjacent superficial epigastric artery and surrounding tissue and small branches were ligated using 10-0 nylon suture. Attempts were made to obtain as great a length of vein as possible, however, branching of this vessel into 3 smaller vessels occurred within 5 mm of its origin at the femoral vein, limiting the length of the vessels in situ to 3-5 mm.
Using a catheter containing MOPS buffered PSS (composition in mM: 145 NaCl, 4.7 KCl, 2.0 CaCl 2 , 1.17 MgSO 4 , 1.2 NaH 2 PO 4 , 0.02 EDTA, 3.0 MOPS, 5.0 glucose), the vein was cannulated at its proximal end, removed from the animal and flushed of blood.
After transferring the vessel to a 1 ml bath containing warm (37 0 C) MOPS-PSS, a second catheter was placed in the distal end of the vessel and perfusion with MOPS-PSS at 37 0 C, bubbled with CO 2 , was commenced. Vessels were perfused from a reservoir at a fixed height and constant pressure (20 mmHg static pressure, which resulted in a flow rate of approximately 1 ml/min). Since the majority of the resistance of this system was in the R-00468-2002.R1 tubing before the vessel, any changes in vessel diameter, which may have occurred during the experiments, were unlikely to have any significant effect on perfusion pressure and thus were unlikely to be of any functional significance in the present study.
At the completion of the experimental protocols (described below) the vessels were removed from the catheters and fixed with 10% formalin. Vessels were then paraffin embedded, cut into 5 µm sections and stained with hematoxylin and eosin.
Vessels were viewed under a light microscope to confirm the presence of endothelium.
Experimental protocols: N values are the number of vessels used for a given protocol. Different protocols were undertaken when two vessels were harvested from the same animal. Only one protocol was carried out in each vessel. Vessels were equilibrated for one hour with collection of bath solution commencing at 30 min. The entire 1 ml bath content was collected and replaced with fresh MOPS-PSS every 10 min.
for the duration of the experiment. Samples were stored at -20 o C until they were assayed, in triplicate, for the stable metabolite of prostacyclin, 6-keto PGF 1 , using the Elisa Technologies 6-keto PGF 1 kit (Neogen Corp., Lexington, KY, product #404310).
This technique has an assay range of 20-2000 pg/ml, with an intra-and inter-assay CV of
10%. An increase in the amount of 6-keto PGF 1 measured in the bath solution was interpreted as an increase in the amount of prostacyclin released from the veins. In all of the following experiments, ATP (100 µM), ACh (10 µM) or adenosine (100 µM) were perfused for 30 minutes to establish a control response. Following a washout period of 10 minutes, during which time the vessels were perfused with regular MOPS-PSS, the veins were treated with an inhibitor (which remained in the perfusate solution until the end of the experiment) or the endothelium was disrupted using one of two methods described below. Vessels were then exposed to the same agonist used to establish the control response.
Protocol 1: Cyclooxygenase Inhibition:
The effect of cyclooxygenase inhibition on ATPmediated prostacyclin release was examined by perfusing the vessels with indomethacin (10 µM, n=6) for 20 minutes prior to establishing a second response to ATP. Time and vehicle (sodium carbonate, 10 mM) controls were performed in additional vessels (n=5 and n=6, respectively).
Protocol 2: Endothelial disruption:
The endothelium was disrupted in one of two ways.
First, an air bubble was perfused through the vessel for several seconds before establishing the second response to ATP (n=10). The second protocol utilized the detergent, deoxycholic acid. This was back-flushed through the vein immediately following the first exposure to ATP (n=6). Vessels were then allowed to stabilize for 20 min. before perfusing with ATP for a second time.
Protocol 3: Purine (P2) receptor blockade:
To determine whether ATP was mediating its effect via P2 receptors, the non-selective antagonist, reactive blue 2 (100 µM, n=6) was added to the perfusate solution 20 minutes prior to the second exposure to ATP. To determine that the effect of this antagonist was specific for ATP, these experiments were repeated in different vessels using ACh in place of ATP (n=5).
Protocol 4: Adenosine receptor blockade:
To determine whether the ATP-mediated release of prostacyclin was due to the hydrolysis of ATP to adenosine, experiments were performed whereby adenosine (100 µM) was used instead of ATP. The P1 receptor antagonist, xanthine amine congener (XAC, 1 µM) was added to the perfusate prior to the second exposure to adenosine (n=5). XAC has been reported to block the A 1 and A 2 R-00468-2002.R1
subtypes of the P1 receptor (10) . In additional vessels (n=4), we examined the effect of XAC (1 µM) on bath concentrations of 6-keto PGF 1 , in response to ATP, to determine whether other metabolites of ATP which act at P1 receptors were responsible for prostacyclin release . As with all of the protocols utilizing inhibitors, XAC was added to the perfusate 20 minutes prior to the second exposure to ATP and remained in the solution for the duration of the experiment.
Drugs: All drugs were purchased from Sigma (St. Louis, MO). ATP was dissolved in distilled water (100mM) and XAC was dissolved in DMSO (100 µM). Both drugs were stored in aliquots at -20 o C and thawed on the day of the experiment.
Indomethacin was dissolved in sodium carbonate (10 mM) and stored in the refrigerator.
Adenosine was dissolved and diluted in MOPS-PSS on the day of the experiment and aliquots of ATP, indomethacin and XAC were diluted in MOPS-PSS on the day of the experiment. Deoxycholic acid (3%) was suspended in distilled water. On the day of the experiment, the solution was heated to 37 O C before back-flushing the vessel.
Analytic and statistical methods:
As each vessel was exposed to ATP or adenosine before and after an experimental protocol, the effects of ATP and of the experimental protocol on bath concentrations of 6-keto PGF 1 were analysed using a 2-way repeated measures ANOVA. All data are means SE. Statistical significance was accepted at P<0.05. The effect of endothelial disruption on 6-keto PGF 1 release is shown in Figure 3 .
ATP (100µM) was associated with an increase in 6-keto PGF 1 concentration from 160 32 pg/ml to 653 139 pg/ml ( Figure 3A , P<0.05, n=10). Disruption of the endothelium using air bubbles significantly decreased ATP-mediated prostacyclin release, but did not completely abolish this response (from 144 33 to 421 102 pg/ml, n=10, Figure 3A ).
However, when the venous endothelium was disrupted using deoxycholic acid, the response to ATP was totally abolished ( Figure 3B , P<0.05, n=6).
The non-selective P2 receptor antagonist, reactive blue 2 (100 µM), was shown to significantly decrease ATP-stimulated increases in 6-keto PGF 1 concentration (from 537 111 to 205 82 pg/ml, P<0.05, n=6, Figure 4A ). In contrast, 100 µM reactive blue 2 was without effect on ACh-stimulated increases in 6-keto PGF 1 concentration ( Figure   4B , n=5).
ATP-stimulated increases in 6-keto PGF 1 were not altered by the adenosine (P1)
receptor antagonist, XAC (1 µM, n=4, Figure 5A ) and adenosine (100 µM) was not associated with any increase in bath concentration of 6-keto PGF 1 from these veins We also sought to clarify whether ATP was exerting its effect via direct stimulation of purine P2 receptors or whether a metabolite such as adenosine was mediating the effect. The results show that the non-selective P2 antagonist, reactive blue 2, did inhibit ATP-mediated prostacyclin release. In addition, the adenosine receptor antagonist, XAC, had no effect upon the response elicited by ATP while direct application of adenosine did not stimulate the release of prostacyclin. These results rule out a role for adenosine receptors in mediating this effect and suggest that ATP is exerting its effect via direct stimulation of P2 receptors on the venular endothelium. metabolites of arachidonic acid (17, 21) . Most recently, we established that inhibition of cyclooxygenase, with indomethacin, only attenuated the functional dilation of arterioles that were paired with venules (14) . These studies collectively suggest that increases in skeletal muscle metabolism are associated with the release of a cyclooxygenase product from the venular endothelium, which can influence the diameter of the adjacent arteriole.
In 1995, Ellsworth and colleagues (9) demonstrated that red blood cells could release ATP under hypoxic and low pH conditions. As such conditions occur in the venous circulation during exercise, we hypothesized that ATP might play a role in functional hyperemia. We have shown that ATP infused into a venule running parallel to an arteriole results in dilation of the cremasteric arteriole (15) . This effect of ATP was shown to be dependent upon an intact venular endothelium and was inhibited when indomethacin was applied globally to the entire cremaster preparation. These studies support a role for ATP in control of vascular tone and further support our hypothesis that cyclooxygenase metabolites from the venular endothelium can influence arteriolar diameter. Furthermore, a recent study demonstrated that venous plasma ATP concentration progressively increased with incremental exercise suggesting that circulating ATP levels were tightly coupled to the oxygenation of hemoglobin in healthy humans (12) .
In the present study, we aimed to provide direct evidence for ATP-stimulated release of prostacyclin from veins. Veins were cannulated at both ends and were mounted in a 1 ml chamber containing physiological salt solution. This set up allowed us to administer the ATP intraluminally and measure the prostacyclin release abluminally.
Addition of ATP to the perfusion solution resulted in the release of prostacyclin into the R-00468-2002.R1 bath solution. These results are consistent with our previous work where we showed that ATP-mediated prostacyclin release from small veins was a calcium-dependent response (5) . We further confirmed that we were measuring a metabolite of the cyclooxygenase pathway by blocking the response with indomethacin.
Red blood cells contain millimolar concentrations of ATP (18) . Although recent studies have measured venous plasma concentrations of ATP in the range of 6-7 µM during exercise (12) , it is questionable as to whether levels such as that used in our study would be achieved under normal physiological conditions. However, we have demonstrated in vivo (hamster cremaster), that venular infusions of 100 µM ATP (15) resulted in diameter changes comparable to those observed during contraction of the same muscle (17) . The assay used in the present study produced highly variable results and we chose a relatively high concentration of ATP in the hope that we would observe that for the small venules the ratio of volume to surface area is quite small suggesting that the effective prostacyclin concentration around venules may actually be higher than in the isolated veins. Whether this response is physiological relevant is difficult to answer.
Iloprost, a stable analog of prostacyclin will cause a vasodilation of arterioles at a concentration of 1000 pg/ml (11) . The current studies show 6-keto-PGF 1 , increasing from ~100 to 600 pg/ml. With similar vasoactive responses between iloprost and prostacyclin (Frisbee personal communication), the analysis suggests that the prostacyclin concentration around the venules would be even higher, which would cause a vasodilation. Until we are able to directly measure the 6-keto PGF 1 release from the venules it will be difficult to answer this question.
In our previous study, although it was highly probable, we did not confirm that present, thus, this suggestion is entirely speculative. Alternatively, it is possible that the mechanism via which air bubbles inactivate endothelial cells is not by removal but rather by dehydration. Again, the partial attenuation of responses following air bubbles may reflect only partial damage to the endothelium.
To further examine the contribution of the endothelium to the ATP-mediated release of prostacyclin, we used deoxycholic acid to inactivate the endothelial cells.
Deoxycholic acid has been reported to remove membrane proteins without actually removing the endothelial cells (26), thus, rendering them inactive. Studies using deoxycholic acid have demonstrated that this compound is very effective at eliminating endothelium-dependent relaxation without altering endothelium-independent relaxation (1, 7, 8, 24) . Furthermore, Cusma-Pelogia and colleagues (8) showed that inactivation of the endothelium using this substance did not alter phenylephrine-or norepinephrineinduced constriction nor did it alter the morphology of the medial smooth muscle cells.
Under light microscopy we confirmed that endothelial cells were still present following treatment with deoxycholic acid and that the smooth muscle layer was still intact.
However, following the administration of deoxycholic acid, ATP-mediated 6-keto PGF 1 release was completely abolished. These studies confirm that ATP-mediated prostacyclin release from hamster epigastric veins is endothelium-dependent and are consistent with studies using isolated arterial preparations (2) and cultured endothelial cells (4, 5, 20) .
Throughout these experiments, we were faced with large variations in basal levels of 6-keto PGF 1 . This was particularly evident in the group of vessels used for the air perfusion. It is likely that amongst the other groups of vessels, variations in basal concentrations of 6-keto PGF 1 were due to differences in the number of functional (27) . While the results of our study do not discriminate between P2X and P2Y receptor subtypes, it is interesting to note that the refractory period, or desensitization effect following the first administration of ATP, is consistent with the involvement of a G-protein coupled receptor to which category P2Y but not P2X receptors belong. R-00468-2002.R1 To further support the hypothesis that ATP-stimulated prostacyclin release is mediated by P2 and not P1 receptors, we attempted to stimulate the release of prostacyclin using adenosine. Consistent with others (2, 4, 20, 25) adenosine failed to stimulate the release prostacyclin from these veins. To ensure that the response was not mediated via AMP which also exerts its effect via stimulation of P1 receptors, we tested the non-selective P1 antagonist, XAC, on ATP-stimulated prostacyclin release. This antagonist did not alter the ATP-mediated response. Only one concentration of XAC was utilized in the present study so it is possible that a higher concentration may have had an effect. However, this concentration has been shown to effectively inhibit arteriolar dilations to 100 µM adenosine and to inhibit arteriolar dilations induced by muscle contraction (6, 19) . These results are consistent with others who have demonstrated that neither adenosine or AMP stimulate the release of prostacyclin from endothelial cells (4, 20, 25) .
The results obtained from the present study support our hypothesis that ATP stimulates the release of prostacyclin from venous endothelial cells via activation of P2Y receptors. Neither AMP or adenosine are likely to be involved in this response, however, we cannot rule out the possibility that ADP, which, like ATP, exerts its effects via P2Y
receptors, is playing a role. These results support a role for the venous endothelium in control of vascular tone.
Perspectives:
Skeletal muscle blood flow is regulated to meet the metabolic needs of the tissue.
The vasculature is arranged as a series successively branching arterioles, all of which 
